CC chemokine receptor 5 δ32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients

Journal of Infectious Diseases

Volumn 186, Issue 12, 2002, Pages 1726-1732

  Wit, Ferdinand W N M ^a   Van Rij, Ronald P ^a   Weverling, Gerrit Jan ^a   Lange, Joep M A ^a   Schuitemaker, Hanneke ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; BLOOD LEVEL; DISEASE COURSE; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS INHIBITION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE COUNT; MALE; POLYMORPHISM, GENETIC; RECEPTORS, CCR5; RECEPTORS, CHEMOKINE; RETROSPECTIVE STUDIES; RNA, VIRAL; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME;

EID: 0037115095     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/345677     Document Type: Article

References (34)

1. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381:661-6.
2. 4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381:667-73.
3. Benkirane M, Jin DY, Chun RF, Koup RA, Jeang KT. Mechanism of trans-dominant inhibition of CCR5-mediated HIV-1 infection by ccr5Δ32. J Biol Chem 1997; 272:30603-6.
4. Huang Y. Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996; 2:1240-3.
5. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86:367-77.
6. Dean M, Carrington M. Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273:1856-62.
7. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382:722-5.
8. Stewart GJ, Ashton LJ, Biti RA, et al. Increased frequency of CCR-5 delta 32 heterozygotes among long-term non-progressors with HIV-1 infection. The Australian Long-Term Non-Progressor Study Group. AIDS 1997; 11:1833-8.
9. de Roda Husman AM, Koot M, Cornelissen M, et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 1997; 127:882-90.
10. Ioannidis JP, Rosenberg PS, Goedert JJ, et al. Effects of CCR5-delta32, CCR2-641, and SDF-1 3′A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann Intern Med 2001: 135:782-95.
11. Smith MW, Dean M, Carrington M, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 1997;277:959-65.
12. Kostrikis LG, Huang Y, Moore JP, et al. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med 1998:4:350-3.
13. Yamashita TE, Phair JP, Munoz A, et al. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS 2001:15:735-46.
14. Guérin S, Meyer L, Theodorou I, et al. CCR5 delta32 deletion and response to highly active antiretroviral therapy in HIV-1-infected patients. AIDS 2000; 14:2788-90.
15. Valdez H. Purvis SF, Lederman MM, Fillingame M, Zimmerman PA. Association of the CCR5Δ32 mutation with improved response to antiretroviral therapy. JAMA 1999;282:734.
16. O'Brien TR, McDermott DH. Ioannidis JP, et al. Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy. AIDS 2000; 14:821-6.
17. Brumme ZL, Chan KJ, Dong W, et al. CCR5Δ32 and promoter polymorphisms are not correlated with initial virological or immunological treatment response. AIDS 2001; 15:2259-66.
18. Bratt G. Karlsson A, Leandersson AC, Albert J, Wahren B, Sandstrom E. Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment. AIDS 1998: 12:2193-202.
19. Reijers MH, Weverling GJ, Jurriaans S. et al. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet 1998; 352: 185-90.
20. Reijers MH, Weverling GJ, Jurriaans S, et al. The ADAM study continued: Maintenance therapy after 50 weeks of induction therapy. AIDS 2001; 15: 129-31.
21. Foudraine NA, Jurriaans S, Weverling GJ, et al. Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: A randomized controlled trial. Antivir Ther 2001;6:55-62.
22. Foudraine NA, de Jong JJ, Jan Weverling G, et al. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine. AIDS 1998; 12:1513-9.
23. van Griensven GJ, Tielman RA, Goudsmit J, et al. Risk factors and prevalence of HIV antibodies in homosexual men in the Netherlands. Am J Epidemiol 1987: 125:1048-57.
24. Weverling GJ, Lange JM, Jurriaans S, et al. Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. AIDS 1998; 12:F117-22.
25. van Rij RP, de Roda Husman AM, Brouwer M, Goudsmit J, Coutinho RA, Schuitemaker H. Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to conversion to SI virus variants. J Infect Dis 1998; 178:1806-11.
26. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992; 41(RR-17):1-19.
27. Lathey JL, Tierney C, Chang SY, et al. Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy. J Infect Dis 2001; 184:1402-11.
28. Koot M, van Leeuwen R, de Goede RE, et al. Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. J Infect Dis 1999; 179:254-8.
29. Michael NL, Chang G, Louie LG, et al. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 1997;3:338-40.
30. Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent anti-retroviral therapy. N Engl J Med 1999; 340:1614-22.
31. Imamichi H, Crandall KA, Natarajan V. et al. Human immunodeficiency virus type I quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy. J Infect Dis 2001; 183:36-50.
32. Kuster H, Opravil M, Ott P, et al. Treatment-induced decline of human immunodeficiency virus-1 p24 and HIV-1 RNA in lymphoid tissue of patients with early human immunodeficiency virus-1 infection. Am J Pathol 2000; 156:1973-86.
33. Fischer M, Gunthard HF, Opravil M, et al. Residual HIV-RNA levels persist for up to 2.5 years in peripheral blood mononuclear cells of patients on potent antiretroviral therapy. AIDS Res Hum Retroviruses 2000; 16:1135-40.
34. Gunthard HF, Frost SD, Leigh-Brown AJ, et al. Evolution of envelope sequences of human immunodeficiency virus type I in cellular reservoirs in the setting of potent antiviral therapy. J Virol 1999;73:9404-12.